Subscribe

6 - McKesson

Eric Klein

America’s largest pharmaceutical distributor slips one spot on the 500 this year, but the continued strength of its distribution business–serving as the middleman between manufacturers and pharmacies–lifted revenues 3% in 2017. The acquisition of Rexall Health powered some of that growth as did trends like the nation’s climbing drug prices and rising drug utilization rates. McKesson also moved ahead with its plan to divest its technology businesses in deals with Change Healthcare and Allscripts. The company, along with the country’s other large drug distributors, remains a target of litigation over its alleged role in the nation’s opioid epidemic.

Key Metrics & Financials (Last Fiscal Year)

Previous Rank5
Revenues ($M)$198533
Revenue Percent Change3.1%
Profits ($M)$5070.0
Profits Percent Change124.5%
Assets ($M)$60969
Market Value — as of March 29, 2018 ($M)$29067
Employees64500

More from FORTUNE

Company Facts

Employees64500
SectorWholesalers
IndustryWholesalers: Health Care
HQ LocationSan Francisco
CEOJohn H. Hammergren
CEO Title-
Websitewww.mckesson.com
Years on Fortune 500 List24

See Full List

Outbrain

More from FORTUNE